• Report Adverse Event or Product Quality Complaint
  • Global Site
AstraZeneca Medical Information
  • Prescribing Information
  • Resources
    • Congress Library
    • Our Pipeline
    • AZ Clinical Trials
    • Externally Sponsored Scientific Research
  • Connect
    • Send MIR
    • Give Feedback

Search Medical Information

American College of Allergy, Asthma & Immunology - 2024 Annual Scientific Meeting

October 24 - 27, 2024

  1. FASENRA (benralizumab)
  2. TEZSPIRE (tezepelumab)
  3. AIRSUPRA (albuterol/budesonide)
  4. Respiratory Unbranded

PDF

Nasal polyps and asthma outcomes in severe eosinophilic asthma patients by nasal polyp status: XALOC-2 real-world evidence program

pdf

Efficacy of Benralizumab and Mepolizumab on Asthma Outcomes in Patients with Eosinophilic Granulomatosis with Polyangiitis

PDF

Tezepelumab Effects on Inflammatory Biomarkers in Patients with Severe, Uncontrolled Asthma by Baseline Biomarker Level

pdf

Clinically Meaningful Lung Function, Asthma Control and Rhinosinusitis Symptom Improvements 6 Months After Tezepelumab Initiation

PDF

Early And Sustained Asthma Control Over 24 Weeks After Tezepelumab Initiation: Real-world ASCENT Study

HTML

Real-world Outcomes Following Biologic Initiation in US Patients with Chronic Rhinosinusitis with Nasal Polyposis

PDF

Does Stepping-Up Inhaled Corticosteroid Maintenance Dose Following a Severe Exacerbation Reduce Future Exacerbation Risk?

PDF

Effects of As-Needed Albuterol–Budesonide Versus Albuterol on Asthma Exacerbations and Lung Function Relative to Persistent Airflow Limitation

pdf

Patterns of As-Needed Use of Albuterol–Budesonide or Albuterol Around a Severe Exacerbation: MANDALA Post-Hoc Analysis

PDF

Disease Burden of Asthma Patients Utilizing Short-Acting Beta2-Agonist Only Inhalers as Rescue in the United States

PDF

Proportion of Patients with Severe Asthma and Comorbid Chronic Rhinosinusitis with Nasal Polyps: Literature Review

PDF

Implementing the Asthma Impairment and Risk Questionnaire and Asthma Checklist into an Asthma Coaching Program

Pdf

Parents/Caregivers, Physicians, C-ACT, and GINA Symptom Control Questions Overestimate Asthma Control for Children 5-11 Years

Need Help?

Contact Us

Send MIR

Submit a Medical Information Request

Disclaimer

Some content may have changed since publication. Some links may require registration/login to access the content. Any attached publications and/or any tables or figures derived from the publications are copyright-protected works. AstraZeneca has obtained permission from the copyright owner to use this work on this site. You may not reproduce, prepare derivative works from, display or distribute this work unless you obtain the permission of the copyright owner, or as otherwise might be permitted by law.

AstraZeneca Logo

This platform is provided as service to healthcare professionals by AstraZeneca Philippines, for medical educational purposes only.

©2024 AstraZeneca. All rights reserved.

PH-10554.

Last Updated 5/24

Contact Us

About Us

AstraZeneca.com

Survey Feedback

Privacy Notice

Legal Notice

Cookie Notice

Global Site

Report Adverse Event or Product Quality Complaint

Privacy NoticeLegal NoticeCookie Notice

Welcome to AstraZeneca Philippines Medical Information

The information provided on this site is intended for use by healthcare professionals practicing in the Philippines, for medical educational purposes only. AstraZeneca does not engage in the promotion of unregistered products or unapproved indications. The dissemination of this information may be subject to different medical and regulatory requirements in other countries

Are you a healthcare professional practicing in the Philippines?

No